In the US, Senexon (senna systemic) is a member of the drug class laxatives and is used to treat Bowel Preparation and Constipation.
US matches:
Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Senexon in the following countries:
International Drug Name Search
Sol.No.37 Manitol may be available in the countries listed below.
Mannitol is reported as an ingredient of Sol.No.37 Manitol in the following countries:
International Drug Name Search
Tari Dog may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Aminophylline is reported as an ingredient of Tari Dog in the following countries:
International Drug Name Search
Selpas may be available in the countries listed below.
Teprenone is reported as an ingredient of Selpas in the following countries:
International Drug Name Search
Supprestral may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Medroxyprogesterone 17α-acetate (a derivative of Medroxyprogesterone) is reported as an ingredient of Supprestral in the following countries:
International Drug Name Search
Salbutalan may be available in the countries listed below.
Salbutamol is reported as an ingredient of Salbutalan in the following countries:
International Drug Name Search
Retisert is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg is implanted into the posterior segment of the affected eye through a pars plana incision.
The implant contains one tablet of 0.59 mg of fluocinolone acetonide. Retisert is designed to release fluocinolone acetonide at a nominal initial rate of 0.6 µg/day, decreasing over the first month to a steady state between 0.3-0.4 µg/day over approximately 30 months. Following depletion of fluocinolone acetonide as evidenced by recurrence of uveitis, Retisert may be replaced.
Caution should be exercised in handling Retisert in order to avoid damage to the implant, which may result in an increased rate of drug release from the implant. Thus, Retisert should be handled only by the suture tab. Care should be taken during implantation and explantation to avoid sheer forces on the implant that could disengage the silicone cup reservoir (which contains a fluocinolone acetonide tablet) from the suture tab. Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure.
Retisert should not be resterilized by any method.
0.59 mg fluocinolone acetonide intravitreal implant.
Surgical placement of Retisert is contraindicated in active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in active bacterial, mycobacterial or fungal infections of the eye.
Use of corticosteroids may result in posterior subcapsular cataract formation.
Based on clinical trials with Retisert, during the 3-year post implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.
Late onset endophthalmitis has been observed. These events are often related to the integrity of the surgical wound site. Careful attention to assure tight closure of the scleral wound and the integrity of the overlying conjunctiva at the wound site is important.
Potential complications accompanying intraocular surgery to place Retisert into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.
Following implantation of Retisert, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.
Prolonged use of corticosteroids may result in elevated IOP and/or glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Patients must be monitored for elevated IOP.
Based on clinical trials with Retisert, within 3-years post implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure. (see 6.1 Clinical Trials Experience - Ocular Events section).
In vitro stability studies show that the strength of the adhesive bond between the silicone cup reservoir and the suture tab is reduced with prolonged hydration, indicating a potential for the separation of these components. The suture tab composition is a silicone elastomer reinforced with a polyester mesh. Physicians should periodically monitor the integrity of the implant by visual inspection.
Retisert should be used with caution in patients with a history of a viral, bacterial, mycobacterial or fungal infection of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella.
Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.
Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections (bacterial, fungal, and viral). In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term application of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used.
Since resistance to infections is known to be reduced by corticosteroids, simultaneous bilateral implantation should not be carried out, in order to limit the potential for bilateral post-operative infection.
Ocular administration of corticosteroids has also been associated with delayed wound healing and perforation of the globe where there is thinning of the sclera.
The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
The available safety data includes exposure to Retisert in patients with chronic non-infectious uveitis affecting the posterior segment in two multicenter controlled clinical trials. Patients were randomized to dosage regimens of 0.59 mg or 2.1 mg implants.
The most frequently reported ocular adverse events were cataract, increased intraocular pressure, procedural complication, and eye pain. These events occurred in approximately 50 - 90% of patients. Cataract includes aggravated cataract, and posterior capsular opacification. Procedural complications includes post-op complication, post-op wound complication, post-op wound site erythema, and wound dehiscense.
Based on clinical trials with Retisert, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery. IOP lowering medications to lower intraocular pressure were required in approximately 77% of patients; filtering surgeries were required to control intraocular pressure in 37% of patients.
Ocular adverse events occurring in approximately 10 - 40% of patients in decreasing order of incidence were ocular/conjunctival hyperemia, reduced visual acuity, glaucoma, conjunctival hemorrhage, blurred vision, abnormal sensation in the eye, eye irritation, maculopathy, vitreous floaters, hypotony, pruritus, ptosis, increased tearing, vitreous hemorrhage, dry eye, eyelid edema, macula edema and visual disturbance.
Ocular adverse events occurring in approximately 5 - 9% of patients in decreasing order of incidence were eye discharge, photophobia, blepharitis, corneal edema, iris adhesions, choroidal detachment, diplopia, eye swelling, retinal detachment, photopsia, retinal hemorrhage and hyphema.
The most frequently reported non-ocular adverse event was headache (33%). Other non-ocular adverse events occurring in approximately 5-20% of patients in decreasing order of incidence were nasopharyngitis, arthralgia, sinusitis, dizziness, pyrexia, upper respiratory tract infection, influenza, vomiting, nausea, cough, back pain, limb pain, and rash.
Pregnancy Category C
No adequate animal reproduction studies have been conducted with fluocinolone acetonide.
Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Fluocinolone acetonide when administered subcutaneously at a dose of 0.13 mg/kg/day (approximately 10,000 times the daily clinical dose of Retisert), during days 6 to 18 of pregnancy in the rabbit, induced abortion at the end of the third and at the beginning of the fourth gestational week. When administered subcutaneously to rats and rabbits during gestation at a maternal toxic dose of 50 µg/kg/day (approximately 4,000 times the clinical dose of Retisert), fluocinolone acetonide caused abortions and malformations in a few surviving fetuses.
There are no adequate and well-controlled studies in pregnant women. Retisert should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether ocular administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when Retisert is implanted in a nursing woman.
Safety and effectiveness in pediatric patients below the age of 12 years have not been established.
No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 µg/day, decreasing over the first month to a steady state between 0.3-0.4 µg/day over approximately 30 months. The drug substance is the synthetic corticosteroid fluocinolone acetonide, represented by the following structural formula:
C24H30F2O6 Mol. Wt. 452.50
Chemical Name: Pregna - 1,4 - diene - 3,20 - dione,6,9 - difluoro - 11,21 - dihydroxy - 16,17 - [(1 - methyl - ethylidene)bis(oxy)] - ,(6α,11β ,16α)-.
Fluocinolone acetonide is a white crystalline powder, insoluble in water, and soluble in methanol. It has a melting point of 265-266ºC.
Each Retisert consists of a tablet containing 0.59 mg of the active ingredient, Fluocinolone Acetonide, USP, and the following inactives: microcrystalline cellulose, polyvinyl alcohol, and magnesium stearate.
Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.
There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids are capable of producing a rise in intraocular pressure.
In a subset of patients who received the intravitreal implant, and had blood samples taken at various times (weeks 1, 4 and 34) after implantation, plasma levels of fluocinolone acetonide were below the limit of detection (0.2 ng/mL) at all times. Aqueous and vitreous humor samples were assayed for fluocinolone acetonide in a further subset of patients. While detectable concentrations of fluocinolone acetonide were seen throughout the observation interval (up to 34 months), the concentrations were highly variable, ranging from below the limit of detection (0.2 ng/mL) to 589 ng/mL.
Long-term animal studies have not been performed on Retisert to evaluate the carcinogenic potential or the effect on fertility of fluocinolone acetonide.
Fluocinolone acetonide was not genotoxic in vitro in the Ames test, the mouse lymphoma TK assay, or in vivo in the mouse bone marrow micronucleus assay.
In two randomized, double-masked, multicenter controlled clinical trials, 224 patients with chronic (a one year or greater history) non-infectious uveitis affecting the posterior segment of one or both eyes were randomized to receive a 0.59 mg Retisert. The primary efficacy endpoint in both trials was the rate of recurrence of uveitis affecting the posterior segment of the study eye in the 34 week pre-implantation period compared to the rate of recurrence in the 34 week post-implantation period. Uveitis recurrence rates at 1, 2, and 3 year post-implantation were also compared to the 34 week pre-implantation period.
Detailed results are shown in table 1 below:
| ||
| Time Point | Study 1 | Study 2 |
| N=108 | N=116 | |
Uveitis Recurrence Rates*† N (%) | ||
| 34 Weeks Pre-implantation | 58 (53.7) | 46 (39.7) |
| 34 Weeks Post-implantation | 2 (1.8) | 15 (12.9) |
| 1 Year Post-implantation | 4 (3.7) | 15 (12.9) |
| 2 Years Post-implantation | 11 (10.2) | 16 (13.8) |
| 3 Years Post-implantation | 22 (20.4) | 20 (17.2) |
| 3 Years‡ Post-implantation | 33 (30.6) | 28 (24.1) |
The implant consists of a tablet encased in a silicone elastomer cup containing a release orifice and a polyvinyl alcohol membrane positioned between the tablet and the orifice. The silicone elastomer cup assembly is attached to a silicone elastomer suture tab with silicone adhesive. Each Retisert is approximately 3 mm x 2 mm x 5 mm.
Each implant is stored in a clear polycarbonate case within a foil pouch within a Tyvek peelable overwrap. Each packaged implant is provided in a carton which includes the package insert.
NDC 24208-416-01
Storage:
Store in the original container at 15° - 25°C (59° - 77°F). Protect from freezing.
Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of Retisert.
As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place Retisert into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, temporary decreased visual acuity, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.
Following implantation of Retisert, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.
Based on clinical trials with Retisert, within 3 years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure. (see 6.1 Clinical Trials Experience - Ocular Events section).
Based on clinical trials with Retisert, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.
MANUFACTURER INFORMATION
Revised May 2011
Marketed by:
Bausch & Lomb Incorporated
Rochester, NY 14609
Manufactured by:
Bausch & Lomb Incorporated
Waterford, Ireland
U.S. Patent # 6,217,895
U.S. Patent # 6,548,078
™/® denote trademarks of Bausch & Lomb Incorporated.
© Bausch & Lomb Incorporated
9028005
NDC 24208-416-01
Bausch & Lomb
Retisert™
(fluocinolone acetonide intravitreal implant) 0.59 mg
STERILE
FOR INTRAVITREAL IMPLANTATION ONLY
Rx only
Contents: One Sterile Retisert™ (fluocinolone acetonide intravitreal implant) 0.59 mg
| Retisert fluocinolone acetonide implant | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA021737 | 04/08/2005 | |
| Labeler - Bausch & Lomb Incorporated (196603781) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Bausch & Lomb Ireland | 985018928 | MANUFACTURE | |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Sicor, S.p.A. | 429369713 | API MANUFACTURE | |
Rotpunkt Apotheke Reisedragées may be available in the countries listed below.
Caffeine is reported as an ingredient of Rotpunkt Apotheke Reisedragées in the following countries:
Dimenhydrinate is reported as an ingredient of Rotpunkt Apotheke Reisedragées in the following countries:
International Drug Name Search
Sultrisan may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfadiazine is reported as an ingredient of Sultrisan in the following countries:
Trimethoprim is reported as an ingredient of Sultrisan in the following countries:
International Drug Name Search
Neo Franvet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Neo Franvet in the following countries:
International Drug Name Search
Napamide may be available in the countries listed below.
Indapamide is reported as an ingredient of Napamide in the following countries:
Indapamide hemihydrate (a derivative of Indapamide) is reported as an ingredient of Napamide in the following countries:
International Drug Name Search
Solclor may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chlortetracycline hydrochloride (a derivative of Chlortetracycline) is reported as an ingredient of Solclor in the following countries:
International Drug Name Search
Generic Name: ibuprofen (EYE bue PROE fen)
Brand Names: Advil, Advil Childrens, Advil Junior Strength, Advil Liquigel, Advil Migraine, Advil Pediatric, Children's Ibuprofen Berry, Genpril, IBU, Midol IB, Midol Maximum Strength Cramp Formula, Motrin Childrens, Motrin IB, Motrin Infant Drops, Motrin Junior Strength, Motrin Migraine Pain, Nuprin
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen works by reducing hormones that cause inflammation and pain in the body.
Ibuprofen is used to reduce fever and treat pain or inflammation caused by many conditions such as headache, toothache, back pain, arthritis, menstrual cramps, or minor injury.
Ibuprofen may also be used for purposes not listed in this medication guide.
Get emergency medical help if you have chest pain, weakness, shortness of breath, slurred speech, or problems with vision or balance.
Call your doctor at once if you have symptoms of stomach bleeding such as black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.
Do not use ibuprofen just before or after heart bypass surgery (coronary artery bypass graft, or CABG).
This medicine may also cause serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and can occur without warning while you are taking ibuprofen, especially in older adults.
Ask a doctor or pharmacist if it is safe for you to take this medication if you have:
a history of heart attack, stroke, or blood clot;
heart disease, congestive heart failure, high blood pressure;
a history of stomach ulcers or bleeding;
asthma;
polyps in your nose;
systemic lupus erythematosus (SLE);
a bleeding or blood clotting disorder; or
if you smoke.
Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.
The ibuprofen chewable tablet must be chewed before you swallow it.
If you take ibuprofen for a long period of time, your doctor may want to check you on a regular basis to make sure this medication is not causing harmful effects. Do not miss any scheduled visits to your doctor.
Since ibuprofen is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
chest pain, weakness, shortness of breath, slurred speech, problems with vision or balance;
black, bloody, or tarry stools, coughing up blood or vomit that looks like coffee grounds;
swelling or rapid weight gain;
urinating less than usual or not at all;
nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
bruising, severe tingling, numbness, pain, muscle weakness; or
severe headache, neck stiffness, chills, increased sensitivity to light, and/or seizure (convulsions).
Less serious side effects may include:
upset stomach, mild heartburn, diarrhea, constipation;
bloating, gas;
dizziness, headache, nervousness;
skin itching or rash;
blurred vision; or
ringing in your ears.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medicines you use, especially:
aspirin or other NSAIDs such as naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Arthrotec, Cambia, Cataflam, Voltaren, Flector Patch, Pennsaid, Solareze), indomethacin (Indocin), meloxicam (Mobic), and others;
heart or blood pressure medicine such as benazepril (Lotensin), enalapril (Vasotec), lisinopril (Prinivil, Zestril), quinapril (Accupril), ramipril (Altace), and others;
lithium (Eskalith, Lithobid);
diuretics (water pills) such as furosemide (Lasix);
methotrexate (Rheumatrex, Trexall);
steroids (prednisone and others); or
a blood thinner such as warfarin (Coumadin, Jantoven).
This list is not complete and other drugs may interact with ibuprofen. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: Advil Pediatric side effects (in more detail)
Generic Name: ocular lubricant (OK yoo lar LOO bri kant)
Brand Names: Artificial Tears, Celluvisc, Clear Eyes CLR, Comfort Tears, Dry Eye Relief, GenTeal, Isopto Tears, Lacri-Lube S.O.P., Lacrisert, Lubricant Eye Drops, Moisture Drops, Oasis Tears, Opti-Free Rewetting Drops, optive, Refresh, Soothe, Sterilube, Systane, Systane Balance, Tears Again, Tears Naturale, Tears Renew, TheraTears, Ultra Fresh, Visine Tears
There are many brands and forms of ocular lubricant available and not all are listed on this leaflet.
Ocular lubricant is a solution specially formulated to moisten the eyes.
Ocular lubricant may also be used for purposes not listed in this medication guide.
There are many brands and forms of ocular lubricant available and not all are listed on this leaflet.
Ask a doctor or pharmacist if it is safe for you to use this medicine if you have any type of infection in your eye.
Do not allow the dropper or tube tip to touch any surface, including the eyes or hands. If the dropper or tube becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.
This medication may cause blurred vision. Be careful if you drive or do anything that requires you to be able to see clearly.
Ask a doctor or pharmacist if it is safe for you to use this medicine if you have any type of infection in your eye.
Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.
To apply the eye drops:
Tilt your head back slightly and pull down your lower eyelid to create a small pocket. Hold the dropper above the eye with the tip down. Look up and away from the dropper as you squeeze out a drop, then close your eye.
Use only the number of drops your doctor has prescribed.
Gently press your finger to the inside corner of the eye (near your nose) for about 1 minute to keep the liquid from draining into your tear duct. If you use more than one drop in the same eye, wait about 5 minutes before putting in the next drop.
Do not use the eye drops if the liquid has changed colors or has particles in it.
To apply the ointment:
Tilt your head back slightly and pull down your lower eyelid to create a small pocket. Hold the ointment tube with the tip pointing toward this pocket. Look up and away from the tip.
Squeeze out a ribbon of ointment 1/2-inch long into the lower eyelid pocket without touching the tip of the tube to your eye. Look down and close your eyes for a few minutes. Rolling your eyes around gently will help spread the ointment evenly.
After opening your eyes, you may have blurred vision for a short time. Avoid driving or doing anything that requires you to be able to see clearly.
Do not allow the dropper or tube tip to touch any surface, including the eyes or hands. If the dropper or tube becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.
Since ocular lubricant is used on an as needed basis, you are not likely to miss a dose.
An overdose of ocular lubricant is not expected to be dangerous.
This medication may cause blurred vision. Be careful if you drive or do anything that requires you to be able to see clearly.
Avoid using other medications in your eyes during treatment with ocular lubricant unless your doctor tells you to.
severe burning, stinging, or eye irritation after using the medication;
eye pain; or
vision changes.
Less serious side effects may include:
mild eye burning or irritation;
itching or redness of your eyes;
watery eyes;
blurred vision; or
unpleasant taste in your mouth.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
It is not likely that other drugs you take orally or inject will have an effect on ocular lubricant used in the eyes. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Seoanin may be available in the countries listed below.
Trapidil is reported as an ingredient of Seoanin in the following countries:
International Drug Name Search
Selumito may be available in the countries listed below.
Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Selumito in the following countries:
International Drug Name Search
Oxybutynine HCl Merck may be available in the countries listed below.
Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Oxybutynine HCl Merck in the following countries:
International Drug Name Search
Soleton may be available in the countries listed below.
Zaltoprofen is reported as an ingredient of Soleton in the following countries:
International Drug Name Search
Sparflox may be available in the countries listed below.
Sparfloxacin is reported as an ingredient of Sparflox in the following countries:
International Drug Name Search
Semerial may be available in the countries listed below.
Gabapentin is reported as an ingredient of Semerial in the following countries:
International Drug Name Search
Generic Name: methamphetamine (METH am FET a meen)
Brand names: Desoxyn, Desoxyn Gradumet
Methamphetamine is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control.
Methamphetamine is used to treat attention deficit hyperactivity disorder (ADHD). It is also used to treat obesity after other diets or medications have been tried without successful weight loss.
Methamphetamine may also be used for other purposes not listed in this medication guide.
Long-term use of methamphetamine can slow a child's growth. Tell your doctor if the child using this medication is not growing or gaining weight properly.
Do not use this medication if you are allergic to methamphetamine or if you have:
heart disease or moderate to severe high blood pressure (hypertension);
arteriosclerosis (hardening of the arteries);
overactive thyroid;
glaucoma;
severe anxiety, tension, or agitation; or
if you have a history of drug or alcohol addiction.
If you have any of these conditions, you may need a dose adjustment or special tests to safely use this medication:
a congenital heart defect;
high blood pressure;
heart failure, heart rhythm disorder, or recent heart attack;
a personal or family history of mental illness, psychotic disorder, bipolar illness, depression, or suicide attempt;
diabetes; or
tics (muscle twitches) or Tourette's syndrome.
Long-term use of methamphetamine can slow a child's growth. Tell your doctor if the child using this medication is not growing or gaining weight properly.
Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.
Your doctor may occasionally change your dose to make sure you get the best results from this medication.
If you are taking methamphetamine for weight loss and your appetite gradually increases, do not take more of the medication to suppress appetite. Stop taking methamphetamine and call your doctor.
To be sure this medication is helping your condition, your doctor will need to see you on a regular basis. Do not miss any scheduled visits.
This medication can cause you to have unusual results with certain medical tests. Tell any doctor who treats you that you are using methamphetamine.
See also: Methamphetamine dosage (in more detail)
Take the missed dose as soon as you remember. If it is almost time for your next dose, or if it is already evening, skip the missed dose and take the medicine the next morning. Taking this medicine late in the day can cause sleep problems. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include restlessness, tremor, muscle twitches, rapid breathing, confusion, hallucinations, panic, aggressiveness, unexplained muscle pain or tenderness, muscle weakness, fever or flu symptoms, and dark colored urine. These symptoms may be followed by depression and tiredness. Other overdose symptoms include nausea, vomiting, diarrhea, stomach pain, uneven heartbeats, feeling light-headed, fainting, seizure (convulsions), or coma.
Do not take methamphetamine late in the day. A dose taken too late in the day can cause sleep problems (insomnia).
Avoid drinking fruit juices or taking vitamin C at the same time you take methamphetamine. These can make your body absorb less of the medicine.
fast, pounding, or uneven heartbeats;
feeling light-headed, fainting;
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure); or
tremor, restlessness, hallucinations, unusual behavior, or motor tics (muscle twitches).
Less serious side effects may include:
headache or dizziness;
sleep problems (insomnia);
dry mouth or an unpleasant taste in your mouth;
diarrhea, constipation;
loss of appetite, weight loss; or
loss of interest in sex, impotence, or difficulty having an orgasm.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Obesity:
For short-term (i.e., a few weeks) use in Exogenous Obesity:
One 5 mg tablet should be taken one-half hour before each meal. Treatment should not exceed a few weeks in duration.
Methamphetamine may be used as an adjunct in a regimen of weight reduction based on caloric restriction, for patients in whom obesity is refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs.
Usual Pediatric Dose for Attention Deficit Disorder:
>= 6 years:
Initial Dose: 5 mg once or twice a day is recommended.
Daily dosage may be raised in increments of 5 mg at weekly intervals until an optimum clinical response is achieved. The usual effective dose is 20 to 25 mg daily. The total daily dose may be given in two divided doses daily.
Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.
Methamphetamine therapy is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
Decrements in the predicted growth (i.e., weight gain and/or height) rate have been reported with the long-term use of stimulants in children. Therefore, patients requiring long-term therapy should be carefully monitored.
Drug treatment is not indicated in all cases of the behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability and impulsivity. It should be considered only in light of the complete history and evaluation of the child. The decision to prescribe methamphetamine tablets should depend on the physician's assessment of the chronicity and severity of the child's symptoms and their appropriateness for his/her age. Prescription should not depend solely on the presence of one or more of the behavioral characteristics.
Usual Pediatric Dose for Obesity:
Tell your doctor about all other medications you use, especially:
insulin;
cold medicines (decongestants);
phenothiazines such as chlorpromazine (Thorazine), prochlorperazine (Compazine, Compro), promethazine (Pentazine, Phenergan, Anergan, Antinaus), thioridazine (Mellaril), and others;
an antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), clomipramine (Anafranil), desipramine (Norpramin), imipramine (Tofranil), or nortriptyline (Pamelor).
This list is not complete and there may be other drugs that can interact with methamphetamine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: methamphetamine side effects (in more detail)
Serozid may be available in the countries listed below.
Ceftazidime is reported as an ingredient of Serozid in the following countries:
International Drug Name Search
Solmucalm may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of Solmucalm in the following countries:
Chlorphenamine maleate (a derivative of Chlorphenamine) is reported as an ingredient of Solmucalm in the following countries:
International Drug Name Search
Bay-O-Pet Cats may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Praziquantel is reported as an ingredient of Bay-O-Pet Cats in the following countries:
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Bay-O-Pet Cats in the following countries:
International Drug Name Search
Nitropack may be available in the countries listed below.
Nitroglycerin is reported as an ingredient of Nitropack in the following countries:
International Drug Name Search
Accidental overdose of products that contain iron is a leading cause of fatal poisoning in children younger than 6 years old. Keep this and all medicines out of the reach of children. In case of accidental ingestion, call the poison control center or doctor at once.
Treating or preventing a lack of vitamins or minerals before, during, and after pregnancy and while breast-feeding. It may also be used for other conditions as determined by your doctor.
Gesticare DHA is a vitamin and mineral combination. It provides vitamins and minerals to the body to help meet nutritional requirements.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Gesticare DHA. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Gesticare DHA. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Gesticare DHA may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Gesticare DHA as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Gesticare DHA.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; dark or discolored stools; diarrhea; nausea; stomach upset; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; blood or streaks of blood in the stools; stomach pain or cramping.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Gesticare DHA side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include black, tarry stools; chest pain; lack of feeling alert; loss of balance; seizure; severe nausea, vomiting, diarrhea, or stomach pain; shortness of breath; sluggishness; trouble breathing; unusual tiredness or weakness; unusually pale skin; weak pulse.
Store Gesticare DHA at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Gesticare DHA out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Gesticare DHA. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Piraska may be available in the countries listed below.
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Piraska in the following countries:
International Drug Name Search
Sogestart may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfadimidine sodium salt (a derivative of Sulfadimidine) is reported as an ingredient of Sogestart in the following countries:
Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Sogestart in the following countries:
International Drug Name Search
Softvit-E may be available in the countries listed below.
Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Softvit-E in the following countries:
International Drug Name Search
Solavert may be available in the countries listed below.
Sotalol hydrochloride (a derivative of Sotalol) is reported as an ingredient of Solavert in the following countries:
International Drug Name Search
Sogecoli may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Colistin is reported as an ingredient of Sogecoli in the following countries:
International Drug Name Search
